Holen Sie sich die Stockscreener-App
92.59
0.06%
0.4336
Schlusskurs vom Vortag:
$93.02
Offen:
$92
24-Stunden-Volumen:
187.46K
Relative Volume:
0.15
Marktkapitalisierung:
$4.54B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.89M
KGV:
-23.75
EPS:
-3.8976
Netto-Cashflow:
$-172.97M
1W Leistung:
-3.25%
1M Leistung:
+0.32%
6M Leistung:
-17.96%
1J Leistung:
+53.16%
1-Tages-Spanne:
$91.89
$93.80
1-Wochen-Bereich:
$91.89
$98.00
52-Wochen-Spanne:
$44.42
$151.02
Celcuity Inc Stock (CELC) Company Profile
Firmenname
Celcuity Inc
Sektor
Branche
Telefon
763-392-0767
Adresse
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
92.69 | 4.55B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
521.93 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
801.48 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.19 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.46 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.62 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | Citizens | Mkt Outperform |
| 2025-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | Eingeleitet | Guggenheim | Buy |
| 2025-07-01 | Fortgesetzt | Stifel | Buy |
| 2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-22 | Eingeleitet | Stifel | Buy |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-07 | Eingeleitet | Jefferies | Buy |
| 2021-07-29 | Eingeleitet | Cowen | Outperform |
| 2021-07-27 | Eingeleitet | Needham | Buy |
| 2021-01-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-11 | Fortgesetzt | Craig Hallum | Buy |
| 2018-11-20 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Celcuity Inc Aktie (CELC) Neueste Nachrichten
Celcuity at Wells Fargo healthcare conference: launch, data in focus By Investing.com - Investing.com Canada
Celcuity Stock Price Forecast. Should You Buy CELC? - StockInvest.us
Celcuity To Participate in Upcoming Investor Conferences - The Manila Times
How Investors May Respond To Celcuity (CELC) sNDA For REVTORPYK In PIK3CA-Mutant Breast Cancer - simplywall.st
Celcuity (CELC): Landmark Approval Collides With A Costly Launch - Yahoo Finance
Celcuity submits application for breast cancer drug expansion - Investing.com
Celcuity’s three-drug breast cancer treatment cut progression or death risk 50% vs. alpelisib - Stock Titan
Celcuity Inc (CELC) Stock News Today - tradingkey.com
Celcuity (CELC) Q2 2026 Earnings Call Transcript - AOL.com
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff? - Stocktwits
Celcuity (CELC) Quarter in Focus: EPS Comes in Below Forecast in the Current Update; Closing Move: Shares Move 2.79% Down in the Available RecordEarnings Weakness Phase - vinanet.vn
E Fund Management Co. Ltd. Purchases New Holdings in Celcuity, Inc. $CELC - MarketBeat
Celcuity (NASDAQ: CELC) insider updates stock holdings - Stock Titan
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating, Cuts Target Price to $173 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Celcuity's (CELC) "Market Outperform" Rating Reiterated at Citizens Jmp - MarketBeat
Celcuity awaits FDA review for second factory to launch cancer drug - Endpoints News
Guggenheim raises Celcuity stock price target on drug pricing data By Investing.com - Investing.com Nigeria
Guggenheim raises Celcuity stock price target on drug pricing data - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update By Investing.com - Investing.com South Africa
Getting To A First Product Approval With Celcuity's Brian Sullivan｜Business Of Biotech - finance.biggo.com
Citizens reiterates Celcuity stock rating ahead of drug launch By Investing.com - Investing.com South Africa
Citizens reiterates Celcuity stock rating ahead of drug launch - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Investors to Inquire about Securities Investigation - The National Law Review
Brian Sullivan: The $20 Million Bet That Resurrected Pfizer's Shelved Cancer Drug - finance.biggo.com
Is Celcuity (CELC) A Bargain As Losses Widen Ahead Of Its First Launch? - Yahoo Finance
How Investors May Respond To Celcuity (CELC) Winning FDA Nod For Revtopik Amid Wider Quarterly Loss - Yahoo Finance
The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status - simplywall.st
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail
Celcuity (NASDAQ:CELC) Stock Rating Lowered by Wall Street Zen - MarketBeat
Needham cuts Celcuity stock price target on updated revenue model By Investing.com - Investing.com Australia
Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS - MarketBeat
H.C. Wainwright Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $155 - Moomoo
Celcuity (CELC) Q2 2026 Ergebniskonferenz: REVTORPYK-Markteinführung für Ende Q3 geplant - TradingKey
Celcuity (CELC) Q2 2026 Earnings Call: REVTORPYK Launch Set for Late Q3 - TradingKey
Celcuity's (CELC) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings - MarketBeat
Celcuity remains a Buy as FDA approval and stro... - Pluang
Stifel cuts Celcuity stock price target on refined market model - Investing.com
Stifel cuts Celcuity stock price target on refined market model By Investing.com - Investing.com Australia
Celcuity (NASDAQ:CELC) Given New $140.00 Price Target at Needham & Company LLC - MarketBeat
Celcuity: REVTORPYK Is Now A Commercial Story (NASDAQ:CELC) - Seeking Alpha
Celcuity (NASDAQ:CELC) Given New $150.00 Price Target at Stifel Nicolaus - MarketBeat
Celcuity Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Celcuity Analysts Slash Their Forecasts After Q2 Loss - Benzinga
Celcuity Inc. Stock 12‑Month Price Target Cut to $160.64, Implies 85% Upside - TradingView
Needham cuts Celcuity stock price target on updated revenue model - Investing.com
Finanzdaten der Celcuity Inc-Aktie (CELC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.30%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):